Saltar al contenido

Cris Bergerot, PhD

@crisbergerot.bsky.social did:plc:c7uckvugvdgto5clyo7p63uh

Advancing oncology care through research, innovation, and multidisciplinary collaboration. Passionate about patient-centered solutions, PROs, HRQOL, and evidence-based practices, w a focus on #GUOnc, #GeriOnc & #PallOnc #ASCO25 FCOI: http://bit.ly/344gKxq

En Bluesky desde el

Seguidores
544
Siguiendo
202
Posts
98
Días en rankings
0

Resumen

Cris Bergerot, PhD (@crisbergerot.bsky.social) es un usuario de Bluesky que se unió el 28 noviembre 2024. Tiene 544 seguidores, sigue a 202 cuentas y ha publicado 98 posts.

Apariciones en rankings

Los mejores días en que los posts de esta cuenta entraron en la lista diaria de Debya.

Esta cuenta aún no ha aparecido en un ranking diario.

Posts que le gustaron recientemente

Me gusta públicos de la red Bluesky.

  • American Society of Clinical Oncology@ascocancer.bsky.social

    And the answer was ... D! Erdafitinib causes ocular toxicity; a baseline ophthalmic exam is required. Did you get it right? Let us know in the comments! Subscribe to ASCO-SEP® today: bit.ly/47OmqN7 ASCO members get 20% off; additional discounts available.

    Ver post
  • American Society of Clinical Oncology@ascocancer.bsky.social

    New Living Guideline: Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I to III Breast Cancer. The new Living Guideline covers the use of medical therapies for stage I-III hormone receptor-positive, HER2-negative breast cancer. Learn more: https://bit.ly/4spJjjv

    Ver post
  • American Society of Clinical Oncology@ascocancer.bsky.social

    Dr. Sumanta Pal of @cityofhope.bsky.social and @ryannipp.bsky.social of OU Health Stephenson Cancer Center discuss high-impact research presented at #ASCOQLTY26 on the latest episode of the #ASCODailyNews Podcast: https://bit.ly/4zg53kt

    Ver post
  • International Kidney Cancer Coalition@ikccorg.bsky.social

    We are proud to continue our partnership with the American Association for Cancer Research (AACR) to support the AACR Scholar-in-Training Award! 🗓️ Application Deadline: 10 November 2026 🔗 Learn more and apply: buff.ly/yx1Y0QV

    Ver post
  • KidneyCAN@kidneycan.bsky.social

    No two #kidneycancer journeys are the same. Built with KidneyCAN & Eisai, Kompass can help guide you to tailored resources and support that fit where you are today. Explore for yourself at KidneyCancerKompass.com.

    Ver post

Inicia sesión para ver más

Cuentas que bloquea

En Bluesky los bloqueos son registros públicos.

Esta cuenta no bloquea a nadie.